• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Basic Mechanisms of JAK Inhibition.

作者信息

Lin Chung Ma, Cooles Faye Ah, Isaacs John D

机构信息

Translational and Clinical Research Institute, Newcastle University and Musculoskeletal Unit, Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, United Kingdom.

出版信息

Mediterr J Rheumatol. 2020 Jun 11;31(Suppl 1):100-104. doi: 10.31138/mjr.31.1.100. eCollection 2020 Jun.

DOI:10.31138/mjr.31.1.100
PMID:32676567
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7361186/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f2a/7361186/a8b2149daddc/MJR-31-Suppl-1-100-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f2a/7361186/a8b2149daddc/MJR-31-Suppl-1-100-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f2a/7361186/a8b2149daddc/MJR-31-Suppl-1-100-g001.jpg

相似文献

1
Basic Mechanisms of JAK Inhibition.JAK抑制的基本机制
Mediterr J Rheumatol. 2020 Jun 11;31(Suppl 1):100-104. doi: 10.31138/mjr.31.1.100. eCollection 2020 Jun.
2
Selective JAK inhibitors in development for rheumatoid arthritis.用于治疗类风湿关节炎的选择性 JAK 抑制剂。
Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. doi: 10.1517/13543784.2014.918604. Epub 2014 May 12.
3
Real-world study comparing the efficacy of Janus kinase inhibitors in patients with difficult-to-treat rheumatoid arthritis.真实世界研究比较了 Janus 激酶抑制剂在治疗困难的类风湿关节炎患者中的疗效。
Clin Rheumatol. 2024 Nov;43(11):3285-3292. doi: 10.1007/s10067-024-07117-w. Epub 2024 Sep 7.
4
JAK-STAT inhibitors: Immersing therapeutic approach for management of rheumatoid arthritis.JAK-STAT 抑制剂：类风湿关节炎治疗管理的浸入式治疗方法。
Int Immunopharmacol. 2020 Sep;86:106731. doi: 10.1016/j.intimp.2020.106731. Epub 2020 Jun 23.
5
JAK inhibitors for the treatment of rheumatoid arthritis.用于治疗类风湿性关节炎的JAK抑制剂。
Immunol Med. 2020 Dec;43(4):148-155. doi: 10.1080/25785826.2020.1770948. Epub 2020 Jun 5.
6
Janus kinase (JAK) inhibitors significantly reduce the humoral vaccination response against SARS-CoV-2 in patients with rheumatoid arthritis.Janus 激酶（JAK）抑制剂显著降低了类风湿关节炎患者对 SARS-CoV-2 的体液疫苗应答。
Clin Rheumatol. 2022 Dec;41(12):3707-3714. doi: 10.1007/s10067-022-06329-2. Epub 2022 Aug 15.
7
Chemical JAK inhibitors for the treatment of rheumatoid arthritis.用于治疗类风湿性关节炎的化学JAK抑制剂。
Expert Opin Pharmacother. 2016 Nov;17(16):2215-2225. doi: 10.1080/14656566.2016.1241237. Epub 2016 Oct 8.
8
Comparative efficacy and safety of Janus kinase inhibitors and biological disease-modifying antirheumatic drugs in rheumatoid arthritis: a systematic review and network meta-analysis.类风湿关节炎中Janus激酶抑制剂与生物改善病情抗风湿药的疗效及安全性比较：一项系统评价与网状Meta分析
Ther Adv Musculoskelet Dis. 2021 Mar 21;13:1759720X21999564. doi: 10.1177/1759720X21999564. eCollection 2021.
9
Making a prescribing choice for rheumatoid arthritis: a focus on small molecule drugs vs. biologics for the most favourable patient outcome.为类风湿性关节炎做出处方选择：聚焦小分子药物与生物制剂以实现最有利的患者预后。
Expert Opin Pharmacother. 2023 Sep-Dec;24(16):1791-1798. doi: 10.1080/14656566.2023.2247325. Epub 2023 Aug 14.
10
Adverse cardiovascular events in rheumatoid arthritis patients treated with JAK inhibitors: An analysis of postmarketing spontaneous safety reports.JAK 抑制剂治疗类风湿关节炎患者的心血管不良事件：上市后自发安全性报告分析。
Semin Arthritis Rheum. 2024 Aug;67:152461. doi: 10.1016/j.semarthrit.2024.152461. Epub 2024 May 17.

引用本文的文献

1
Evaluating Current and Emergent JAK Inhibitors for Alopecia Areata: A Narrative Review.评估斑秃的现有和新型JAK抑制剂：一项叙述性综述
Dermatol Ther (Heidelb). 2025 Aug 12. doi: 10.1007/s13555-025-01517-9.
2
Deliver CEBPE via cartilage targeting Lipid nanoparticle to block CEBPE-LTF-STAT3 positive feedback loop for efficient treatment of cartilage endplate degeneration.通过软骨靶向脂质纳米颗粒递送CEBPE，以阻断CEBPE-LTF-STAT3正反馈回路，从而有效治疗软骨终板退变。
Mater Today Bio. 2025 Jun 28;33:102027. doi: 10.1016/j.mtbio.2025.102027. eCollection 2025 Aug.
3
Advances in the treatment of systemic lupus erythematosus.

本文引用的文献

1
Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.比较巴瑞替尼、乌帕替尼和托法替尼对人白细胞亚群细胞因子信号转导的调控作用。
Arthritis Res Ther. 2019 Aug 2;21(1):183. doi: 10.1186/s13075-019-1964-1.
2
JAK-inhibitors. New players in the field of immune-mediated diseases, beyond rheumatoid arthritis.JAK 抑制剂。类风湿关节炎之外，免疫介导性疾病领域的新玩家。
Rheumatology (Oxford). 2019 Feb 1;58(Suppl 1):i43-i54. doi: 10.1093/rheumatology/key276.
3
Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases.
系统性红斑狼疮治疗的进展
Nat Rev Drug Discov. 2025 Jul 17. doi: 10.1038/s41573-025-01242-0.
4
A systematic literature review of Janus kinase inhibitors for the treatment of systemic sclerosis.关于用于治疗系统性硬化症的 Janus 激酶抑制剂的系统文献综述。
J Scleroderma Relat Disord. 2025 May 22:23971983251342697. doi: 10.1177/23971983251342697.
5
A Case Series and Review of Febrile-Infection Related Epilepsy Syndrome (FIRES).发热感染相关癫痫综合征（FIRES）的病例系列报告及综述
Children (Basel). 2025 Apr 10;12(4):485. doi: 10.3390/children12040485.
6
Interindividual variability and its impact on the effectiveness of Janus kinase inhibitors in rheumatoid arthritis treatment.个体间变异性及其对类风湿关节炎治疗中Janus激酶抑制剂疗效的影响。
Front Med (Lausanne). 2025 Mar 28;12:1512501. doi: 10.3389/fmed.2025.1512501. eCollection 2025.
7
Real-World Effectiveness and Safety of Upadacitinib in Patients with Ulcerative Colitis: A Systematic Review and Meta-Analysis.乌帕替尼治疗溃疡性结肠炎患者的真实世界有效性和安全性：一项系统评价和荟萃分析
J Clin Med. 2025 Mar 25;14(7):2232. doi: 10.3390/jcm14072232.
8
Pharmacological evaluation of drug therapies in Aicardi-Goutières syndrome: insights from patient-derived neural stem cells.Aicardi-Goutières综合征药物治疗的药理学评估：来自患者来源神经干细胞的见解
Front Pharmacol. 2025 Mar 20;16:1549183. doi: 10.3389/fphar.2025.1549183. eCollection 2025.
9
Neurological Adverse Events Associated with the Use of Janus Kinase Inhibitors: A Pharmacovigilance Study Based on Vigibase.与使用 Janus 激酶抑制剂相关的神经系统不良事件：一项基于 Vigibase 的药物警戒研究。
Pharmaceuticals (Basel). 2025 Mar 11;18(3):394. doi: 10.3390/ph18030394.
10
Immune Memory: A New Frontier in Treating Recurrent Inflammatory Skin Diseases.免疫记忆：治疗复发性炎症性皮肤病的新前沿。
Clin Rev Allergy Immunol. 2025 Mar 18;68(1):31. doi: 10.1007/s12016-025-09039-0.
选择性 JAK 抑制剂：在炎症和自身免疫性疾病中的前景。
BioDrugs. 2019 Feb;33(1):15-32. doi: 10.1007/s40259-019-00333-w.
4
The Jakinibs in systemic lupus erythematosus: progress and prospects.系统性红斑狼疮中的 Jakinibs：进展与展望。
Expert Opin Investig Drugs. 2019 Jan;28(1):85-92. doi: 10.1080/13543784.2019.1551358. Epub 2018 Nov 26.
5
Real-world Evidence versus Randomized Controlled Trial: Clinical Research Based on Electronic Medical Records.真实世界证据与随机对照试验：基于电子病历的临床研究。
J Korean Med Sci. 2018 Jun 26;33(34):e213. doi: 10.3346/jkms.2018.33.e213. eCollection 2018 Aug 20.
6
Receptor-mediated dimerization of JAK2 FERM domains is required for JAK2 activation.受体介导的 JAK2 FERM 结构域二聚化是 JAK2 激活所必需的。
Elife. 2018 Jul 25;7:e38089. doi: 10.7554/eLife.38089.
7
The role of the JAK/STAT signal pathway in rheumatoid arthritis.JAK/STAT信号通路在类风湿关节炎中的作用。
Ther Adv Musculoskelet Dis. 2018 Jun;10(5-6):117-127. doi: 10.1177/1759720X18776224. Epub 2018 May 19.
8
Are Janus Kinase Inhibitors Superior over Classic Biologic Agents in RA Patients?Janus 激酶抑制剂在类风湿关节炎患者中优于经典生物制剂吗？
Biomed Res Int. 2018 May 10;2018:7492904. doi: 10.1155/2018/7492904. eCollection 2018.
9
JAK inhibition as a therapeutic strategy for immune and inflammatory diseases.JAK 抑制作为治疗免疫和炎症性疾病的策略。
Nat Rev Drug Discov. 2017 Dec;16(12):843-862. doi: 10.1038/nrd.2017.201. Epub 2017 Nov 6.
10
The interferon gene signature is increased in patients with early treatment-naive rheumatoid arthritis and predicts a poorer response to initial therapy.干扰素基因特征在早期未接受过治疗的类风湿性关节炎患者中增加，并预示对初始治疗的反应较差。
J Allergy Clin Immunol. 2018 Jan;141(1):445-448.e4. doi: 10.1016/j.jaci.2017.08.026. Epub 2017 Oct 5.